August 2019

Enzalutamide and ADT Reduce Prostate Cancer Progression Risk
Enzalutamide, an androgen receptor inhibitor, when combined with androgen deprivation therapy (ADT)  in metastatic hormone-sensitive prostate cancer, has been shown to increase progression-free survival. Most deaths related to prostate cancer are due to metastatic disease in patients who have not had, or do not respond to, hormone therapy. Read more.


Ice Chips Prevent Hyperalgesia With Oxaliplatin
Baumen et al found that oral cryotherapy with oxaliplatin infusions resulted in less cold sensitivity and a shorter duration of symptoms. The theory behind this involves oral thermal hyperalgesia, and patients who receive chemotherapy may have trouble eating and tasting. Cryotherapy is easy to use and is a very simple fix to potentially help patients receiving oxaliplatin. Read more.

Metabolic Changes May Predict Anthracycline Cardiotoxicity
Chemotherapy-induced cardiotoxicity is a risk associated with many chemotherapy agents, especially anthracyclines. To be able to prevent or identify it early is desirable. Metabolites associated with the mitochondria can undergo changes that are associated with chemotherapy-induced cardiotoxicity. Currently, there is no effective way of predicting which patients will develop cardiotoxicity. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App